SCHEMBL14848166

SCHEMBL14848166

COc1c(C(=O)NCc2ccc(Oc3ccc(F)cc3)cc2)ccn(C)c1=O

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 2/20 0.78
TP53 P04637 2/20 0.51
PPARG P37231 1/20 0.50
PPARD Q03181 1/20 0.50
PPARA Q07869 1/20 0.50
POLB P06746 1/20 0.49
LMNA P02545 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
PDE10A Q9Y233 1/20 0.48
GAA P10253 1/20 0.48
PTGER4 P35408 3/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
PTGER2 P43116 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPK14 Q16539 1/20 0.47
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14847780 0.87 LIPG (1.00) LIPGTP53PPARGPPARDPPARA
SCHEMBL5519468 0.81 LIPG (0.88) LIPGTP53LMNAPDE10AGAA
SCHEMBL755779 0.79 LIPG (0.48) LIPGTP53LMNAGAAHTT
SCHEMBL12636541 0.77 LIPG (0.52) LIPGTP53PPARGPPARDPPARA
SCHEMBL15953971 0.77 LIPG (0.80) LIPGTP53PPARGPPARDPPARA
SCHEMBL12697369 0.77 KMT2A (0.62) TP53POLBLMNAGAAMAPT
SCHEMBL12634657 0.75 PLA2G1B (0.50) LIPGPPARGPPARDPPARAPOLB
SCHEMBL755373 0.74 CTSD (0.45) LIPGPOLBLMNAGAAMAPT
SCHEMBL12636189 0.74 LIPG (0.48) LIPGTP53PPARGPPARDPPARA
SCHEMBL15953377 0.74 LIPG (0.75) LIPGPPARGPPARDPPARAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760839-B1 PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-11-25 EP disclosed
US-8993557-B2 Pyridinedione carboxamide inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2015-03-31 US disclosed
US-8993557-B2 Pyridinedione carboxamide inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2015-03-31 US disclosed
US-20140235608-A1 PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-21 US disclosed
US-20140235608-A1 PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-21 US disclosed
WO-2013049104-A1 PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235608-A1 PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, PNLIP, LPL LIPG 1/4885TP53 4830/4885PPARG 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.